Stocktoria
SELLAS Life Sciences Group, Inc. SLS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2008-03-12
SELLAS Life Sciences Group, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1.0M | $7.6M |
| R&D expense | — | — | — | — | $15.7M |
| SG&A expense | $12.3M | $12.4M | $13.9M | $12.6M | $11.3M |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$42.0M | -$25.3M |
| Income tax | $0 | $0 | $0 | $0 | -$237,000 |
| Net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | -$20.7M |
| EPS (diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
| Operating cash flow | -$28.4M | -$35.4M | -$31.4M | -$23.8M | -$26.0M |
| Cash & equivalents | $71.8M | $13.9M | $2.5M | $17.1M | $21.4M |
| Total assets | $78.3M | $19.4M | $6.2M | $20.9M | $26.3M |
| Total liabilities | $7.5M | $10.0M | $14.2M | $16.1M | $5.9M |
| Shareholders' equity | $70.9M | $9.5M | -$8.0M | $4.9M | $20.3M |
Source: SEC EDGAR filings · CIK 0001390478 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.